Yüklüyor......
Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential
Severe asthma is characterized by major impairment of quality of life, poor symptom control and frequent exacerbations. Inflammatory, clinical and causative factors identify different phenotypes and endotypes of asthma. In the last few years, new treatment options have allowed for targeted treatment...
Kaydedildi:
| Yayımlandı: | Ther Adv Chronic Dis |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5076744/ https://ncbi.nlm.nih.gov/pubmed/27803792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622316659863 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|